J Neurol. 2019 Oct 16. doi: 10.1007/s00415-019-09577-6. [Epub ahead of print]

Risks associated with oral deferiprone in the treatment of infratentorial superficial siderosis.

Sammaraiee Y¹, Banerjee G¹, Farmer S², Hylton B³, Cowley P², Eleftheriou P³, Porter J³, Werring DJ⁴.

Author information

1

Stroke Research Centre, Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Russell Square House, London, WC1N 5EE, UK.

2

National Hospital for Neurology and Neurosurgery, London, UK.

3

Department of Haematology, University College London, London, UK.

4

Stroke Research Centre, Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Russell Square House, London, WC1N 5EE, UK. [email protected].

Abstract

OBJECTIVE:

Deferiprone is an iron chelator that has recently been used to treat patients with infratentorial superficial siderosis (iSS). It is considered to have a generally favourable safety profile but concerns have been raised due to the risk of agranulocytosis. We aimed to evaluate the safety and tolerability of oral deferiprone as a treatment for patients with iSS.

METHODS:

We present a case series of 10 consecutive patients presenting with classical iSS treated with deferiprone.

RESULTS:

Ten patients were followed up for a mean period of 2.3 years (range 0.5-5.5 years). Four patients (40%) were withdrawn from treatment because of treatment-related side effects. The reasons for treatment discontinuation were neutropenic sepsis (n = 3) and fatigue (n = 1). In 2 out of the 3 cases of neutropenic sepsis, patients initially developed neutropenia without sepsis. The mean time to neutropenic sepsis following deferiprone was 1.2 years (range 0.3-2.5) with mean neutrophil count of 0.4 (range 0.3-0.5). Six patients (60%) reported no change in neurological function while on treatment, and four patients (40%) reported that their condition deteriorated.

CONCLUSIONS:

Deferiprone was poorly tolerated, with 40% of patients withdrawing from treatment, most commonly due to neutropenic sepsis, after an average of 2 years on treatment. This study increases the number of reported cases of agranulocytosis in patients with iSS treated with deferiprone. Clinicians treating iSS patients with deferiprone should be aware that this drug has a potentially life-threatening side effect of neutropenic sepsis, and should ensure that appropriate haematological monitoring is in place.